Galectin-3 (LGALS3)

Overview

Galectin 3 is a member of the galectin family of β-galactoside-binding proteins and is encoded by LGALS3. It is a multifunctional protein implicated in cell–cell and cell–matrix interactions, immune regulation, inflammation, fibrosis, and tumor biology. In biomedical research, galectin 3 is often discussed as both a circulating biomarker and a mechanistic mediator of disease processes, particularly in settings involving tissue injury, chronic inflammation, metabolic dysfunction, and cancer.

Functionally, galectin 3 has been associated with pathways relevant to metabolic dysfunction–associated steatotic liver disease, Metabolic dysfunction associated steatohepatitis (MASH), cardiovascular injury, and neuroinflammation. It is also studied as a therapeutic target in oncology, where galectin-1 and galectin-3 are sometimes considered together because of their overlapping roles in tumor progression, immune evasion, and the hallmarks of cancer. Recent studies have also linked galectin 3 to disease contexts involving obesity, proinflammatory cytokine signaling, TGF-β1 and VEGF-related fibrotic or angiocrine pathways, Parkinson's disease, and a range of solid tumors.

Recent Publications Summary

Recent publications have continued to position Galectin-3 (LGALS3) as a multifunctional target in cancer, inflammatory disease, and tissue remodeling. In pathological retinal neovascularization, single-cell and clinical dataset analyses linked neutrophil infiltration to diabetic retinopathy progression and identified activated microglia as an upstream source of galectin-3 that helped sustain a self-amplifying microglia-neutrophil feedback loop driving aberrant angiogenesis in a mouse oxygen-induced retinopathy model 42555755Aug. In a separate report, galectin-3 was highlighted as an emerging biomarker in hemodialysis patients, where it was grouped among newer markers proposed for mortality risk prediction alongside IL-6, PTX3, sST2, FGF-23, and Klotho 42455729Jul.

Several studies explored galectin-3 as a therapeutic or targeting molecule. A modular theranostic platform used a truncated human galectin-3 as the targeting moiety to direct cargo toward β-galactoside-containing oligosaccharides overexpressed on tumour cell membranes; in vitro and mouse xenograft experiments supported the system’s specificity and flexibility for drug delivery 42363882Jun. Another preclinical study tested the galectin-3 inhibitor TD139, alone or paired with direct current stimulation approaches, in aggressive meningioma models; the authors reported that galectin-3 activated microglia and promoted CD4(+) T-cell polarization toward Th2 and Treg phenotypes, while TD139 combined with stimulation reduced tumor growth and induced anaplastic meningioma cell death in model systems 42363999Jun. A broader medicinal chemistry effort also developed GB1841, an orally available halothiazole glycomimetic with dual galectin-1/galectin-3 inhibitory activity, and showed that selective or dual inhibition reduced LL/2 lung cancer growth in a syngeneic mouse model 42052938Apr.

Beyond oncology, galectin-3 was implicated in systemic and metabolic pathology. In a MASH-associated sarcopenia study, LGALS3 was one of three hepatokines elevated in circulation in mouse models and in sarcopenic patients with advanced chronic liver disease; recombinant LGALS3, like liver-secreted proteins, induced atrophy in C2C12 myotubes and altered mitochondrial metabolism 42270040Jun. In a cisplatin toxicity model, modified citrus pectin was used to modulate galectin expression in rat spleen, where cisplatin increased tissue expression of Gal-1, Gal-3, and Gal-9, and MCP reduced CD3+ T-cell immunoreactivity while also affecting splenic iron handling features 42126478May. Additional reports observed galectin-3-related changes in plasma small extracellular vesicles from obese breast cancer patients, where network analyses linked Gal-3 to EV-associated proteins and validation showed Gal-3 was reduced in small-EVs from cancer samples 42085441May.

What Changes, What Holds

1. Galectin-3 is now implicated in a microglia–neutrophil angiogenic circuit and in dialysis risk stratification
NEW DIRECTION Activated microglia as an upstream source of LGALS3 adds a specific disease mechanism in pathological retinal neovascularization that goes beyond the baseline’s broad roles in inflammation and neuroinflammation; it suggests galectin-3 may help sustain a feed-forward immune loop in diabetic retinopathy rather than merely mark injury 42555755Aug. The hemodialysis biomarker work also extends its use into mortality-risk panels, but remains additive rather than definitive 42455729Jul.

2. Galectin-3 is being used and inhibited as a target, not just observed as a marker, across tumor models
REINFORCES A truncated human galectin-3 targeting module and the dual-inhibitor GB1841 both fit the established view of LGALS3 as a therapeutically actionable galectin family member in cancer, while TD139 further sharpens the mechanistic picture of galectin-3-driven immunomodulation in meningioma models 42363882Jun42052938Apr. The mixed preclinical evidence supports ongoing target validation, but it does not overturn the baseline account of galectin-3 in tumor progression and immune evasion 42363999Jun.

3. Galectin-3 now has a plausible catabolic role in MASH-linked sarcopenia and appears in treatment-related tissue responses
NEW DIRECTION LGALS3 being secreted as a hepatokine that induces myotube atrophy broadens the baseline’s MASH discussion from liver injury and fibrosis into muscle wasting, creating a mechanistic link to sarcopenia that was not previously established 42270040Jun. The cisplatin and obese breast cancer EV findings are ancillary but consistent with galectin-3 as a stress-responsive systemic signal rather than a liver-only or cancer-only marker 42126478May42085441May.

Overview update candidates: galectin-3 as an upstream source in retinal neovascularization; LGALS3 as a hepatokine contributing to MASH-associated sarcopenia.